PMC35 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION  by Dragomir, A et al.
Paris Abstracts A393
testing vaccination strategies. One of the main beneﬁts is that for parameterization 
and identiﬁcation no abstract values are used, so objectivity and traceability are 
assured.
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OBJECTIVES: To identify and critically appraise cost-effectiveness models developed 
to evaluate type 2 diabetes (T2D) treatments and to assess which types of treatment 
effects they capture. METHODS: A systematic search was performed in MEDLINE, 
EMBASE, Centre for Reviews and Dissemination databases at the University of York, 
and Health Economic Evaluation Database for the period to September 2008. The 
websites of Health Technology Assessment (HTA) bodies in different countries were 
also screened for relevant models. For each of the identiﬁed original models, details 
of the structure, data in- and outputs and consistency were extracted and critically 
appraised using published criteria. RESULTS: 78 articles and 41 HTAs reporting rel-
evant economic evaluations were identiﬁed. There were ten models with multiple 
publications, and a further ten models with one associated publication. The critical 
review demonstrated that most of the existing models had the same fundamental 
structure, used similar microsimulation techniques and were based on the same key 
data sources. However, the process for identiﬁcation of relevant data and their syn-
thesis, as well as the selection of outcomes was, at times, inconsistent and lacked 
transparency. The models differed according to which diabetes complications and 
treatment-related adverse events were captured. For example, just one model incor-
porated changes in patient weight, despite the fact that weight gain can be a side effect 
of some treatments, and weight loss a potential beneﬁt of others. CONCLUSIONS: 
Whilst many economic models exist in T2D, most share common features such as the 
model type. Identiﬁed shortcomings are lack of transparency in data identiﬁcation and 
evidence synthesis as well as the selection of the modelled outcomes. Future models 
should aim to include all relevant treatment outcomes, whether these relate to effects 
on underlying diabetes and its complications or to short- or long-term side effects of 
treatment.
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OBJECTIVES: After the introduction of the 7-valent pneumococcal conjugate vaccine 
(Prevnar®) in the US, the incidence of invasive pneumococcal disease (IPD) caused by 
the 7 vaccine serotypes declined dramatically in vaccinated children as well as unvac-
cinated adults (via herd effect beneﬁt). In 2008, a transmission dynamic equation 
model was developed to capture direct and indirect vaccination effects. This model 
accurately predicted the total incidence of IPD (caused by all serotypes) after Prevnar® 
introduction. This original model was reﬁned in the present analysis to predict the 
dynamics of IPD caused by speciﬁc serotypes. METHODS: The model simulates the 
acquisition of asymptomatic carriage of pneumococci and the development of fatal 
and non-fatal IPD among vaccinated and unvaccinated individuals aged 2, 2–4, 5–17, 
18–49, 50–64, and  65 years old. Categories of pneumococcal serotypes include 
PCV7-type (4, 6B, 9V, 14, 18C, 19F, and 23F) and non-PCV7-type (all others). The 
model was calibrated by approximating serotype-speciﬁc US IPD surveillance data 
from the years 1998–2006. RESULTS: The previous model structure ﬁt the disease 
incidence caused by the PCV7 serotypes quite well, but was inadequate to predict 
increases in disease caused by the non-PCV7 serotypes due to serotype replacement. 
Additionally, the surveillance data showed limited increase in IPD caused by non-
PCV7 serotypes in the vaccinated 2-year-old group. A subsequent recalibration and 
reformulation resulted in a revised model able to replicate closely the observed IPD 
incidence stratiﬁed by pneumococcal serotypes. CONCLUSIONS: The revised model 
validates the accuracy of the original model to replicate the incidence of IPD caused 
by PCV7 serotypes and may be used to predict the future incidence of disease given 
the increases in IPD caused by non-PCV7 serotypes.
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Pharmacological strategies for schizophrenia have received increasing attention due to 
the development of new and costly drug therapies. Evaluating their relative costs and 
beneﬁts in Canada requires modeling the natural course of schizophrenia. OBJEC-
TIVES: To develop a Markov model with 1st-order Monte-Carlo simulations to simu-
late the natural course of newly diagnosed schizophrenic patients. METHODS: Six 
discrete disease states deﬁned the Markov model: 1): ﬁrst episode—FE; 2) low depen-
dency state—LDS; 3) high dependency state—HDS; 4) Stable; 5) Well; and 6) Death. 
Patients’ movements between these disease states deﬁned 17 probability transitions 
to be estimated. The model was based on data from the Régie de l’assurance maladie 
du Québec and Med-Echo databases. All individuals aged 0–60 years with a newly 
diagnosis of schizophrenia between 1998 to 2006 were ﬁrst identiﬁed by ICD-9 codes. 
Using this data, 5 Cox proportional hazard models for competing risks were used to 
estimate the 17 probabilities of transition. Validation was conducted by comparing 
the model’s probability transitions’ predictions with the published literature. 
RESULTS: A total of 12,754 individuals were identiﬁed as newly diagnosed patients 
with schizophrenia. After the FE of schizophrenia, 69.8% of patients passed in LDS, 
11.2% in HDS, 1% in death state and 18% in Well state. The mean transition prob-
abilities after one year of follow-up were: FE to Well at 0.28 (oSD  0.10), FE to HDS 
at 0.11 (o0.05), FE to LDS at 0.60 (o0.08) and respectively FE to Death at 0.01 
(o0.01). The corresponding values were similar to those obtained from other published 
models. CONCLUSIONS: This model is the ﬁrst Canadian model incorporating 
transition probabilities adjusted for individual risk factors proﬁles using Canadian 
data. Future applications will include pricing and cost-effectiveness of new therapies 
for schizophrenia.
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OBJECTIVES: To create national weights to project a private database to the US 
insured population controlling not only for socio-demographic factors but also health 
status. METHODS: The Medicare Expenditure Survey was used as the basis of adjust-
ment methodology. First, we subset the data source to the study population, then used 
multivariate logistic regression to construct demographics and case-mix based weights 
that were applied to make the data similar to the national sample. Propensity Score 
Matching and Raking algorithm is combined to create the adjusted weights. The 
socioeconomic characteristics included in the model were the age of the head of the 
household, percentage of the patients who were female, race, geographic region and 
income level. We derived two variables to capture general health status of the member. 
First, Charlson Index scores were generated to capture the level and burden of comor-
bidity. Secondly, we created an indicator variable to represent patients with chronic 
conditions. This variable was derived by convening two physician panels to review all 
medical conditions reported by the survey sample. RESULTS: Private data were more 
likely to be male, white, older, and chronic (p  0.0000). Adjusted weight values for 
the Commercial group ranged from 13.47 to 26.39 with median 16.35. The projected 
US population by private database and MEPS data were similar in terms of socioeco-
nomic and clinical categories. As an outcomes measure, the predicted annual statin 
users from private data was 6,973,034. Statin users are predicted as 6,709,438 using 
MEPS data with MEPS weights. CONCLUSIONS: National projection of a private 
database requires adjustment from not only demographic factors but also case-mix 
differences related to health status. The created weights successfully balanced the 
population in terms of co-morbid conditions and chronic conditions as well as demo-
graphic factors.
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OBJECTIVES: Matching and regression analysis are two approaches to estimate 
average treatment effect. Different matching techniques provide different results. 
Moreover, matching cannot control for unobserved bias. Using ProbChoice algorithm 
and Rosenbaum bounding approach, we aim to show how to choose strongly unmea-
sured variable must inﬂuence the selection process to undermine the implication of 
matching and regression analysis. METHODS: The Surveillance, Epidemiology, and 
End Results (SEER) Data is used for the analysis. For each patient, their hospital of 
care and associated hospital volume is computed. Patients in the high and low volume 
hospitals are matched in seven different ways in terms of demographic and clinical 
characteristics. Treatment costs are compared. The best technique is chosen by Prob-
Choice algorithm. Rosenbaum bonds estimated and Mantel and Haenszel test statistics 
is calculated to provide evidence on the degree to which any signiﬁcance results hinge 
on unconfoundedness assumption. RESULTS: A volume cohort was constructed con-
sisting of 19,375 female SEER-Medicare patients, aged 65, suffering an in situ and/or 
invasive breast cancer during 2003–2005 with surgical treatment performed at 567 
hospitals. Mahalobis matching is the one who created the best balanced comparable 
sets. After the matching, samples were similar in terms of race, comorbidity and 
adjuvant therapies. Under the assumption of no hidden bias, costs were lower of the 
high volume hospitals. (p  0.000). Results were insensitive to a bias that would double 
the odds of being treated high volume hospitals but sensitive to a bias that would 
triple the odds. CONCLUSIONS: There exist several matching techniques and the 
results depend the type of matching chosen. One needs to chose the technique best 
suitable for the data. Rosenbaum bonds provides evidence on sensitivity of the esti-
mated results with respect to unobservable factors that is not controlled by propensity 
score matching.
